Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.76)
# 3,081
Out of 4,853 analysts
62
Total ratings
44.19%
Success rate
-3.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $59 → $66 | $66.18 | -0.27% | 8 | Dec 5, 2024 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $39.30 | -44.02% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.11 | +110.97% | 2 | May 14, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $53 → $46 | $21.10 | +118.01% | 5 | May 13, 2024 | |
| ROIV Roivant Sciences | Maintains: Buy | $16 → $18 | $11.20 | +60.71% | 5 | Apr 3, 2024 | |
| GERN Geron | Maintains: Buy | $4 → $5 | $1.56 | +220.51% | 3 | Mar 15, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.46 | +138.10% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $35.03 | -20.07% | 7 | Jan 9, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Buy | $47 → $52 | $46.80 | +11.11% | 5 | Nov 29, 2023 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.53 | +4,083.01% | 6 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $23 | $1.02 | +2,154.90% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $1.56 | +1,246.15% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $3.54 | +295.48% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $29.60 | -72.97% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $0.34 | +4,589.33% | 2 | Dec 15, 2021 |
Rhythm Pharmaceuticals
Dec 5, 2024
Maintains: Buy
Price Target: $59 → $66
Current: $66.18
Upside: -0.27%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $39.30
Upside: -44.02%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.11
Upside: +110.97%
IDEAYA Biosciences
May 13, 2024
Maintains: Buy
Price Target: $53 → $46
Current: $21.10
Upside: +118.01%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $16 → $18
Current: $11.20
Upside: +60.71%
Geron
Mar 15, 2024
Maintains: Buy
Price Target: $4 → $5
Current: $1.56
Upside: +220.51%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.46
Upside: +138.10%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $35.03
Upside: -20.07%
SpringWorks Therapeutics
Nov 29, 2023
Maintains: Buy
Price Target: $47 → $52
Current: $46.80
Upside: +11.11%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.53
Upside: +4,083.01%
Mar 15, 2023
Maintains: Buy
Price Target: $27 → $23
Current: $1.02
Upside: +2,154.90%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $1.56
Upside: +1,246.15%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $3.54
Upside: +295.48%
May 24, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $29.60
Upside: -72.97%
Dec 15, 2021
Initiates: Neutral
Price Target: $16
Current: $0.34
Upside: +4,589.33%